Collegium Pharmaceutical, Inc. (COLL)
Largest Insider Buys in Sector
COLL Stock Price History Chart
COLL Stock Performance
About Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to …
Insider Activity of Collegium Pharmaceutical, Inc.
Over the last 12 months, insiders at Collegium Pharmaceutical, Inc. have bought $0 and sold $8.37M worth of Collegium Pharmaceutical, Inc. stock.
On average, over the past 5 years, insiders at Collegium Pharmaceutical, Inc. have bought $0 and sold $10.24M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 20,000 shares for transaction amount of $183,600 was made by Brannelly Paul (Executive Vice President & CFO) on 2017‑05‑12.
List of Insider Buy and Sell Transactions, Collegium Pharmaceutical, Inc.
| 2024-09-13 | Sale | EVP and Chief Medical Officer | 9,593 0.0291% | $36.62 | $351,320 | -8.96% | ||
| 2024-09-06 | Sale | EVP and General Counsel | 977 0.0031% | $37.46 | $36,594 | -6.78% | ||
| 2024-09-05 | Sale | EVP and General Counsel | 19,248 0.0608% | $38.30 | $737,198 | -7.79% | ||
| 2024-06-03 | Sale | EVP and General Counsel | 25,000 0.0771% | $32.57 | $814,180 | +7.21% | ||
| 2024-05-28 | Sale | EVP & Chief Financial Officer | 19,710 0.06% | $34.21 | $674,368 | +0.38% | ||
| 2024-05-24 | Sale | EVP & Chief Commercial Officer | 56,807 0.1745% | $33.98 | $1.93M | +0.54% | ||
| 2024-05-23 | Sale | EVP & Chief Commercial Officer | 51,209 0.1565% | $33.82 | $1.73M | +1.54% | ||
| 2024-05-14 | Sale | director | 28,985 0.086% | $32.30 | $936,311 | +2.58% | ||
| 2024-02-29 | Sale | EVP and Chief Medical Officer | 995 0.0031% | $36.76 | $36,580 | -2.85% | ||
| 2024-02-26 | Sale | EVP & Chief Commercial Officer | 10,000 0.0312% | $36.43 | $364,270 | -1.97% | ||
| 2024-01-16 | Sale | EVP & Chief Commercial Officer | 23,560 0.0725% | $32.28 | $760,519 | +8.35% | ||
| 2023-12-21 | Sale | President and CEO | 4,357 0.0134% | $30.38 | $132,377 | +13.45% | ||
| 2023-12-20 | Sale | President and CEO | 26,454 0.0825% | $30.40 | $804,210 | +15.27% | ||
| 2023-12-19 | Sale | President and CEO | 14,516 0.0446% | $30.03 | $435,942 | +15.04% | ||
| 2023-12-18 | Sale | President and CEO | 27,798 0.0854% | $30.04 | $834,935 | +14.96% | ||
| 2023-11-27 | Sale | EVP and General Counsel | 25,600 0.0781% | $25.78 | $660,014 | +33.16% | ||
| 2023-06-26 | Sale | EVP and General Counsel | 17,984 0.0534% | $21.72 | $390,633 | +42.75% | ||
| 2023-06-02 | Sale | President and CEO | 31,272 0.091% | $21.60 | $675,424 | +20.39% | ||
| 2023-06-01 | Sale | President and CEO | 31,272 0.0901% | $22.09 | $690,758 | +16.47% | ||
| 2023-05-31 | Sale | President and CEO | 31,272 0.0903% | $21.87 | $683,797 | +17.90% |
Insider Historical Profitability
| Freund John Gordon | 2949916 9.147% | $29.25 | 1 | 0 | +44.38% | |
| Skyline Venture Partners V LP | 10 percent owner | 2949916 9.147% | $29.25 | 1 | 0 | +44.38% |
| Heron Patrick J | 1887332 5.8522% | $29.25 | 1 | 0 | +44.38% | |
| Frazier Healthcare VI, L.P. | 10 percent owner | 1887332 5.8522% | $29.25 | 1 | 0 | +44.38% |
| TPG Group Holdings (SBS) Advisors, Inc. | 1325253 4.1093% | $29.25 | 1 | 0 | +44.38% |
Institutional Investor Ownership
| BlackRock | $227.71M | 17.93 | 5.87M | +1.36% | +$3.06M | 0.01 | |
| Eventide Asset Management | $102.25M | 8.05 | 2.63M | +0.14% | +$138,315.66 | 1.65 | |
| Pacer Advisors Inc | $100.42M | 7.91 | 2.59M | +18.95% | +$16M | 0.25 | |
| The Vanguard Group | $90.48M | 7.12 | 2.33M | +0.78% | +$696,508.44 | <0.01 | |
| Helm Capital Management LLC | $71.2M | 5.61 | 1.83M | -33.51% | -$35.88M | 2.11 |